Neoadjuvant anti-OX40 (MEDI6469) prior to surgery in head and neck squamous cell carcinoma.
R. Bryan Bell(Takara (United States)), Andrew D. Weinberg(Providence Portland Medical Center), Brendan D. Curti(Providence Portland Medical Center), Allen Cheng(Australian Regenerative Medicine Institute), Joanna Pucilowska(Oregon Health & Science University), Thomas Duhen(AGCO (Netherlands)), Raina Tamakawa(Providence Portland Medical Center), Carmen Ballesteros‐Merino(Cancer Institute (WIA)), Carlo Bifulco(Providence Health & Services), Rom S. Leidner(Providence Portland Medical Center), Bernard A. Fox(Oregon Health & Science University), Ashish Patel(Providence Portland Medical Center), Brady Bernard(Providence Portland Medical Center), Yoshinobu Koguchi(Providence Portland Medical Center), Brian Piening(Providence College), Mark W. Schuster(Providence Portland Medical Center), Rebekka Duhen(Oregon Health & Science University), William L. Redmond(Providence St. Vincent Medical Center), George Morris(Providence Portland Medical Center), Walter J. Urba(Providence Portland Medical Center)
Cited by 27
Related Papers
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.6k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k
Genomic Classification of Cutaneous Melanoma
|Cell|2015|3.3k